{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.3","upperLimit":"52.6","value":"40.5"},{"groupId":"OG001","lowerLimit":"57.2","upperLimit":"74.8","value":"66.4"},{"groupId":"OG002","lowerLimit":"55.7","upperLimit":"83.6","value":"71.1"},{"groupId":"OG003","lowerLimit":"0.1","upperLimit":"17.2","value":"3.3"},{"groupId":"OG004","lowerLimit":"35.5","upperLimit":"64.5","value":"50.0"},{"groupId":"OG005","lowerLimit":"0.0","upperLimit":"8.0","value":"0"},{"groupId":"OG006","lowerLimit":"0.0","upperLimit":"25.9","value":"0"},{"groupId":"OG007","lowerLimit":"0.0","upperLimit":"63.2","value":"0"},{"groupId":"OG008","lowerLimit":"0.5","upperLimit":"39.4","value":"10.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"50"},{"groupId":"OG005","value":"44"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"10"}],"units":"Participants"}],"description":"Objective Response Rate (ORR) is defined as the number of randomized participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on investigator assessments \\\\\\[using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\\\\\\], divided by the number of all randomized participants.\n\nComplete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\\\\\<10 mm.\n\nPartial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg","id":"OG000","title":"Cohort 1: Nivolumab Monotherapy"},{"description":"Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg","id":"OG001","title":"Cohort 2: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg"},{"description":"Nivolumab 3 mg/kg Q2W with Ipilimumab 1 mg/kg twice in six weeks Q6W","id":"OG002","title":"Cohort 3: Nivolumab 3 mg/kg Q2W with Ipilimumab 1 mg/kg Q6W"},{"description":"Cohort 4: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg + Cobimetinib 60 mg","id":"OG003","title":"Cohort 4: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg + Cobimetinib 60 mg"},{"description":"Nivolumab 240 mg + BMS-986016 80 mg","id":"OG004","title":"Cohort 5: Nivolumab 240 mg + BMS-986016 80 mg"},{"description":"Nivolumab FD + Daratumumab 16 mg/kg","id":"OG005","title":"Cohort 6: Nivolumab FD + Daratumumab 16 mg/kg"},{"description":"Nivolumab 3 mg/kg Q2W with Ipilimumab 1 mg/kg Q6W","id":"OG006","title":"MSS: Nivolumab 3 mg/kg Q2W with Ipilimumab 1 mg/kg Q6W"},{"description":"Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg","id":"OG007","title":"Non-MSI-H: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg"},{"description":"Nivolumab 1 mg/kg + Ipilimumab 1 mg/kg","id":"OG008","title":"Non-MSI-H: Nivolumab 1 mg/kg + Ipilimumab 1 mg/kg"}],"paramType":"NUMBER","populationDescription":"All treated participants.","reportingStatus":"POSTED","timeFrame":"From date of randomization to the date of objectively documented progression or the date of subsequent systemic cancer therapy, whichever occurs first (Up to approximately 127 months)","title":"Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment","type":"PRIMARY","unitOfMeasure":"percentage of participants"}